Kovack Advisors’s Humacyte HUMA Stock Holding History

Kovack Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44K	Hold	72,600	–	–	﹤0.01%	996
2025 Q4	$69.7K	Buy	+72,600	New	+$103K	﹤0.01%	995
2023 Q4	–	Sell	-42,000	Closed	-$123K	–	590
2023 Q3	$123K	Buy	42,000 +2,000	+5%	+$6.62K	0.02%	524
2023 Q2	$114K	Buy	40,000 +5,000	+14%	+$18K	0.01%	550
2023 Q1	$108K	Buy	35,000 +10,000	+40%	+$28.4K	0.01%	553
2022 Q4	$52.8K	Buy	+25,000	New	+$75.9K	0.01%	531
2022 Q2	–	Sell	-31,500	Closed	-$222K	–	670
2022 Q1	$222K	Buy	+31,500	New	+$183K	0.02%	624

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Kovack Advisors's HUMA Position: Q1 2026 in Review

Kovack Advisors held its Humacyte (HUMA) position steady in Q1 2026 at 72,600 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Kovack Advisors first reported a position in HUMA in Q1 2022 and has held it in 7 quarters since. The position peaked at $222K in Q1 2022. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

Kovack Advisors held 72,600 shares of Humacyte worth $44K as of Q1 2026.
Kovack Advisors left its Humacyte share count unchanged in Q1 2026.
Humacyte made up ﹤0.01% of Kovack Advisors's portfolio in Q1 2026, its #996 holding.
Kovack Advisors first reported a position in Humacyte in Q1 2022 and has held it in 7 quarters since.
Kovack Advisors's Humacyte position peaked at $222K in Q1 2022.
158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.